Lepu Chuangyi

Lepu Chuangyi is a biotechnology company based in Beijing and a core subsidiary of Lepu Biopharma, specializing in the development of innovative oncology immunotherapies. The company's primary focus is on the PD-1/PD-L1 signaling pathway, utilizing an integrated platform for the discovery and clinical advancement of monoclonal antibodies. Its flagship product, Pucocimab (HX008), is a humanized anti-PD-1 antibody that has gained regulatory approval in China for the treatment of melanoma and MSI-H/dMMR solid tumors. Additionally, the company is advancing LP002, an anti-PD-L1 candidate, through late-stage clinical trials for various cancer indications. Lepu Chuangyi plays a critical role in the broader Lepu Biopharma portfolio by providing foundational checkpoint inhibitor therapies.